158 related articles for article (PubMed ID: 31681433)
41. BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer.
Weber-Lassalle N; Hauke J; Ramser J; Richters L; Groß E; Blümcke B; Gehrig A; Kahlert AK; Müller CR; Hackmann K; Honisch E; Weber-Lassalle K; Niederacher D; Borde J; Thiele H; Ernst C; Altmüller J; Neidhardt G; Nürnberg P; Klaschik K; Schroeder C; Platzer K; Volk AE; Wang-Gohrke S; Just W; Auber B; Kubisch C; Schmidt G; Horvath J; Wappenschmidt B; Engel C; Arnold N; Dworniczak B; Rhiem K; Meindl A; Schmutzler RK; Hahnen E
Breast Cancer Res; 2018 Jan; 20(1):7. PubMed ID: 29368626
[TBL] [Abstract][Full Text] [Related]
42. Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.
Casey MJ; Bewtra C
Fam Cancer; 2004; 3(3-4):265-81. PubMed ID: 15516851
[TBL] [Abstract][Full Text] [Related]
43. Age and Geographical Distribution in Families with BRCA1/BRCA2 Mutations in the Slovak Republic.
Ciernikova S; Tomka M; Kovac M; Stevurkova V; Zajac V
Hered Cancer Clin Pract; 2006 Dec; 4(1):7-11. PubMed ID: 20223009
[TBL] [Abstract][Full Text] [Related]
44. Mutations in BRCA1, BRCA2 and other breast and ovarian cancer susceptibility genes in Central and South American populations.
Jara L; Morales S; de Mayo T; Gonzalez-Hormazabal P; Carrasco V; Godoy R
Biol Res; 2017 Oct; 50(1):35. PubMed ID: 28985766
[TBL] [Abstract][Full Text] [Related]
45. Identification of germline BRCA1 and BRCA2 genetic alterations in Greek breast cancer moderate-risk and low-risk individuals--correlation with clinicopathological data.
Kataki A; Gomatos I; Pararas N; Armakolas A; Panousopoulos D; Karantzikos G; Voros D; Zografos G; Markopoulos C; Leandros E; Konstadoulakis M
Clin Genet; 2005 Apr; 67(4):322-9. PubMed ID: 15733268
[TBL] [Abstract][Full Text] [Related]
46. Hereditary truncating mutations of DNA repair and other genes in BRCA1/BRCA2/PALB2-negatively tested breast cancer patients.
Lhota F; Zemankova P; Kleiblova P; Soukupova J; Vocka M; Stranecky V; Janatova M; Hartmannova H; Hodanova K; Kmoch S; Kleibl Z
Clin Genet; 2016 Oct; 90(4):324-33. PubMed ID: 26822949
[TBL] [Abstract][Full Text] [Related]
47. Investigation of monogenic causes of familial breast cancer: data from the BEACCON case-control study.
Li N; Lim BWX; Thompson ER; McInerny S; Zethoven M; Cheasley D; Rowley SM; Wong-Brown MW; Devereux L; Gorringe KL; Sloan EK; Trainer A; Scott RJ; James PA; Campbell IG
NPJ Breast Cancer; 2021 Jun; 7(1):76. PubMed ID: 34117267
[TBL] [Abstract][Full Text] [Related]
48. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
49. Quantitative Analysis of
Farber-Katz S; Hsuan V; Wu S; Landrith T; Vuong H; Xu D; Li B; Hoo J; Lam S; Nashed S; Toppmeyer D; Gray P; Haynes G; Lu HM; Elliott A; Tippin Davis B; Karam R
Front Oncol; 2018; 8():286. PubMed ID: 30101128
[TBL] [Abstract][Full Text] [Related]
50. Double heterozygous mutation in the BRCA1 and ATM genes involved in development of primary metachronous tumours: a case report.
Andrés R; Menao S; Arruebo M; Quílez E; Cardiel MJ
Breast Cancer Res Treat; 2019 Oct; 177(3):767-770. PubMed ID: 31292799
[TBL] [Abstract][Full Text] [Related]
51. OLA1 gene sequencing in patients with BRCA1/2 mutation-negative suspected hereditary breast and ovarian cancer.
Takahashi M; Chiba N; Shimodaira H; Yoshino Y; Mori T; Sumii M; Nomizu T; Ishioka C
Breast Cancer; 2017 Mar; 24(2):336-340. PubMed ID: 27271530
[TBL] [Abstract][Full Text] [Related]
52. Targeted RNA-seq successfully identifies normal and pathogenic splicing events in breast/ovarian cancer susceptibility and Lynch syndrome genes.
Brandão RD; Mensaert K; López-Perolio I; Tserpelis D; Xenakis M; Lattimore V; Walker LC; Kvist A; Vega A; Gutiérrez-Enríquez S; Díez O; ; de la Hoya M; Spurdle AB; De Meyer T; Blok MJ
Int J Cancer; 2019 Jul; 145(2):401-414. PubMed ID: 30623411
[TBL] [Abstract][Full Text] [Related]
53. Uncovering the Contribution of Moderate-Penetrance Susceptibility Genes to Breast Cancer by Whole-Exome Sequencing and Targeted Enrichment Sequencing of Candidate Genes in Women of European Ancestry.
Dumont M; Weber-Lassalle N; Joly-Beauparlant C; Ernst C; Droit A; Feng BJ; Dubois S; Collin-Deschesnes AC; Soucy P; Vallée M; Fournier F; Lemaçon A; Adank MA; Allen J; Altmüller J; Arnold N; Ausems MGEM; Berutti R; Bolla MK; Bull S; Carvalho S; Cornelissen S; Dufault MR; Dunning AM; Engel C; Gehrig A; Geurts-Giele WRR; Gieger C; Green J; Hackmann K; Helmy M; Hentschel J; Hogervorst FBL; Hollestelle A; Hooning MJ; Horváth J; Ikram MA; Kaulfuß S; Keeman R; Kuang D; Luccarini C; Maier W; Martens JWM; Niederacher D; Nürnberg P; Ott CE; Peters A; Pharoah PDP; Ramirez A; Ramser J; Riedel-Heller S; Schmidt G; Shah M; Scherer M; Stäbler A; Strom TM; Sutter C; Thiele H; van Asperen CJ; van der Kolk L; van der Luijt RB; Volk AE; Wagner M; Waisfisz Q; Wang Q; Wang-Gohrke S; Weber BHF; Genome Of The Netherlands Project ; Ghs Study Group ; Devilee P; Tavtigian S; Bader GD; Meindl A; Goldgar DE; Andrulis IL; Schmutzler RK; Easton DF; Schmidt MK; Hahnen E; Simard J
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884425
[TBL] [Abstract][Full Text] [Related]
54. Identification of a novel mutations BRCA1*c.80 + 3del4 and BRCA2*c.6589delA in Slovak HBOC families.
Konecny M; Vizvaryova M; Zavodna K; Behulova R; Gerykova Bujalkova M; Krivulcik T; Cisarik F; Kausitz J; Weismanova E
Breast Cancer Res Treat; 2010 Jan; 119(1):233-7. PubMed ID: 19011960
[TBL] [Abstract][Full Text] [Related]
55. A Review of Whole-Exome Sequencing Efforts Toward Hereditary Breast Cancer Susceptibility Gene Discovery.
Chandler MR; Bilgili EP; Merner ND
Hum Mutat; 2016 Sep; 37(9):835-46. PubMed ID: 27226120
[TBL] [Abstract][Full Text] [Related]
56.
Concolino P; Gelli G; Rizza R; Costella A; Scambia G; Capoluongo E
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336956
[TBL] [Abstract][Full Text] [Related]
57. Exome sequencing and characterization of 49,960 individuals in the UK Biobank.
Van Hout CV; Tachmazidou I; Backman JD; Hoffman JD; Liu D; Pandey AK; Gonzaga-Jauregui C; Khalid S; Ye B; Banerjee N; Li AH; O'Dushlaine C; Marcketta A; Staples J; Schurmann C; Hawes A; Maxwell E; Barnard L; Lopez A; Penn J; Habegger L; Blumenfeld AL; Bai X; O'Keeffe S; Yadav A; Praveen K; Jones M; Salerno WJ; Chung WK; Surakka I; Willer CJ; Hveem K; Leader JB; Carey DJ; Ledbetter DH; ; Cardon L; Yancopoulos GD; Economides A; Coppola G; Shuldiner AR; Balasubramanian S; Cantor M; ; Nelson MR; Whittaker J; Reid JG; Marchini J; Overton JD; Scott RA; Abecasis GR; Yerges-Armstrong L; Baras A
Nature; 2020 Oct; 586(7831):749-756. PubMed ID: 33087929
[TBL] [Abstract][Full Text] [Related]
58. The Genetic and Molecular Analyses of
Alenezi WM; Milano L; Fierheller CT; Serruya C; Revil T; Oros KK; Behl S; Arcand SL; Nayar P; Spiegelman D; Gravel S; Mes-Masson AM; Provencher D; Foulkes WD; El Haffaf Z; Rouleau G; Bouchard L; Greenwood CMT; Masson JY; Ragoussis J; Tonin PN
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565380
[TBL] [Abstract][Full Text] [Related]
59. Rare and potentially pathogenic variants in hydroxycarboxylic acid receptor genes identified in breast cancer cases.
McGuire Sams C; Shepp K; Pugh J; Bishop MR; Merner ND
BMC Med Genomics; 2021 Dec; 14(1):284. PubMed ID: 34852802
[TBL] [Abstract][Full Text] [Related]
60. Clinical Impact of Polygenic Risk Score for Breast Cancer Risk Prediction in 382 Individuals with Hereditary Breast and Ovarian Cancer Syndrome.
Stiller S; Drukewitz S; Lehmann K; Hentschel J; Strehlow V
Cancers (Basel); 2023 Aug; 15(15):. PubMed ID: 37568754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
